NCT05443516Recruiting
Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus. Recherche de Biomarqueurs de l'activité de la Maladie Chez Des Patients Atteints de Lupus érythémateux disséminé.
Source: ClinicalTrials.gov · Last updated 5 Jul 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this research project is to better understand the origin and clinical significance of two lupus-specific "genetic signatures" (IFN signature and plasma cell signature) in patient subgroups with well-defined clinical characteristics. Our aim is to correlate these genetic signatures with cell activation profiles and the production of specific cytokines in different populations from whole blood and in short-term cultures of these circulating cells.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 17 Jun 2022
- Start date
- 16 Jun 2014
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Diseases
- Lupus (SLE)
- NCT number
- NCT05443516
What you commit to
- Study type: Observational
- Planned participants: 250
- From 16 Jun 2014 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Anticipated non-adherence to therapy.
Other illness
- Antiphospholipid syndrome nephropathy (APSN).
- Medical conditions interfering with outcome evaluations.
Other
- Pregnancy at baseline (pregnancy during follow-up will not lead to exclusion).
- Inability to read and/or sign the informed consent form.
Who the study is looking for
- Fulfilment of the EULAR/ACR classification criteria of SLE.
- 18 years of age or above.
- Incident or Flare biopsy-proven proliferative or membranous LN
Age in the registry: 18 years to 70 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cliniques universitaires Saint-Luc Coordinator of this site? Confirm its status | Brussels | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.